Human races and pharmacogenomics of effective bone treatments

Gynecological Endocrinology

Volumn 20, Issue 1, 2005, Pages 36-44

  Massart, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bone; Human races; Osteoporosis; Pharmacogenomics

Indexed keywords

ALFACALCIDOL; APAI ENDONUCLEASE; BSMI ENDONUCLEASE; CALCITRIOL; CONJUGATED ESTROGEN; ENDONUCLEASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FOKI ENDONUCLEASE; MEDROXYPROGESTERONE ACETATE; POLYADENYLIC ACID; RESTRICTION ENDONUCLEASE; RESTRICTION ENDONUCLEASE PVUII; RESTRICTION ENDONUCLEASE XBAI; TAQI ENDONUCLEASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ALLELE; ARTICLE; ASIAN; CAUCASIAN; DRUG EFFICACY; DRUG SENSITIVITY; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE EXPRESSION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RISK; HISPANIC; HUMAN; MORBIDITY; MORTALITY; NEGRO; OSTEOPOROSIS; PHARMACOGENOMICS; PRIORITY JOURNAL;

CONTINENTAL POPULATION GROUPS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; OSTEOPOROSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 15944366904     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400019437     Document Type: Article

References (55)

1. Ott SM, Chesnut CH 3rd. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989;110:267-74
2. Ott SM, Chesnut CH 3rd. Tolerance to dose of calcitriol is associated with improved density in women with postmenopausal osteoporosis. J Bone Miner Res 1990;5:S186
3. Jensen GF, Meinecke B, Boesen J, et al. Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women. Clin Orthop 1985;192:215-21
4. Christiansen C, Christensen MS, Rodbro P, et al. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981;11:305-9
5. Jensen GF, Christiansen C, Transbol I. Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol 1982;16:515-24
6. Christiansen C, Christensen MS, McNair P, et al. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9
7. Falch JA, Odegaard OR, Finnanger AM, et al. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 1987;221: 199-204
8. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001;86:4098-103
9. Caniggia A, Nuti R, Lore F, et al. Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 1990;39:43-9
10. Ongphiphadhanakul B, Piaseu N, Tung SS, et al. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen. Maturitas 2000;34:179-84
11. Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6
12. Chen JT, Shiraki M, Hasumi K, et al. 1-alpha-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997;20:557-62
13. Gorai I, Chaki O, Taguchi Y, et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcif Tissue Int 1999;65:16-22
14. Shiraki M, Ito H, Orimo H. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner 1993;20:223-34
15. Ushiroyama T, Ikeda A, Sakai M, et al. Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas 2001;40:229-38
16. Orimo H, Shiraki M, Hayashi T, et al. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner 1987;3:47-52
17. Chen M, Chow SN. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study. Clin Endocrinol 2001;55:253-8
18. Sorensen OH, Andersen RB, Christensen MS, et al. Treatment of senile osteoporosis with 1alpha-hydroxyvitamin D3. Clin Endocrinol 1977;7:169s-175s
19. Hoikka V, Alhava EM, Aro A, et al. Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium. Acta Med Scand 1980;207:221-4
20. Dabek JT, Robinson BH, Naik RB, et al. Spinal calcium changes with 1alpha-hydroxyvitamin D3. Clin Endocrinol 1977;7:147s-150s
21. Marshall DH, Nordin BE. The effect of 1alpha-hydroxyvitamin D3 with and without oestrogens on calcium balance in post-menopausal women. Clin Endocrinol 1977;7:159s-168s
22. Recker RR, Davies KM, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999;130:897-904
23. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-5
24. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997;177:115-19
25. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994;40:671-7
26. Holland EF, Leather AT, Studd JW. Increase in bone mass of older postmenopausal women with low mineral bone density after one year of percutaneous oestradiol implants. Br J Obstet Gynaecol 1995;102:238-42
27. Haines CJ, Chung TK, Leung PC, et al. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995;16:529-31
28. Davis JW, Ross PD, Johnson NE, et al. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995;17:369-73
29. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997;27:69-76
30. Massart F, Reginster JY, Brandi ML. Genetics of menopause-associated diseases. Maturitas 2001;40:103-16
31. Gennari L, Becherini L, Falchetti A, et al. Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J Steroid Biochem Mol Biol 2002;81:1-24
32. Ferrari SL, Bonjour JP, Rizzoli R. The vitamin D receptor gene and calcium metabolism. Trends Endocrinol Metab 1998;9:259-64
33. Salamone LM, Glynn NW, Black DM, et al. Determinants of premenopausal bone mineral density: the interplay of genetic and lifestyle factors. J Bone Miner Res 1996;11:1557-65
34. Matsuyama T, Ishii S, Tokita A, et al. Vitamin D receptor genotypes and bone mineral density. Lancet 1995;345:1238-9
35. Hunter D, Major P, Arden N, et al. (2000) A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J Bone Miner Res 2000;15:2276-83
36. Howard G, Nguyen T, Morrison N, et al. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 1995;80:2800-5
37. Graafmans WC, Lips P, Ooms ME, et al. (1997) The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997;12:1241-5
38. Beelman CA, Parker R. (1995) Degradation of mRNA in eukaryotes. Cell 1995;81:179-83
39. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-7
40. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70
41. Ingles SA, Haile RW, Henderson BE, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev 1997;6:93-8
42. Whitfield GK, Remus LS, Jurutka PW, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001;177:145-59
43. Becherini L, Gennari L, Masi L, et al. (2000) Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 2000;9:2043-50
44. Han KO, Moon IG, Kang YS, et al. Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab 1997;82:991-5
45. Deng HW, Li J, Li JL, et al. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum Genet 1998;103:576-85
46. Kobayashi N, Fujino T, Shirogane T, et al. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 2002;41:193-201
47. Ongphiphadhanakul B, Chanprasertyothin S, Payarikul P, et al. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol 2000;52:581-5
48. Kinuta K, Tanaka H, Moriwake T, et al. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000;141:1317-24
49. Salmen T, Heikkinen AM, Mahonen A, et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res 2000;15:315-21
50. Salmen T, Heikkinen AM, Mahonen A, et al. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. J Bone Miner Res 2000;15:2479-86
51. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-82
52. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-74
53. Uehar M, Arai Y, Watanabe S, et al. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 2000;12: 217-25
54. Maruyama H, Toji H, Harrington CR, et al. Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol 2000;57:236-40
55. Lei SF, Deng FY, Liu XH, et al. Polymorphisms of four bone mineral density candidate genes in Chinese populations and comparison with other populations of different ethnicity. J Bone Miner Metab 2003;21:34-42